UBS Keeps Their Buy Rating on Sanofi (SNYNF)

In a report released today, Jo Walton from UBS maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €110.00. The company’s shares closed last Thursday at $92.70.

According to TipRanks, Walton is a 2-star analyst with an average return of -0.1% and a 56.67% success rate.

Currently, the analyst consensus on Sanofi is a Moderate Buy with an average price target of $105.01, implying a 13.28% upside from current levels. In a report released on April 16, Leerink Partners also maintained a Buy rating on the stock with a €100.00 price target.

SNYNF market cap is currently $116.5B and has a P/E ratio of 19.77.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sanofi (SNYNF) Company Description:

Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes & cardiovascular, established prescription products and generics, together with research, development and production activities. This segment also includes all associates whose activities are related to pharmaceuticals. The Consumer Healthcare segment comprises, for all geographical territories, the commercial operations for its Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines. The company was founded in 1973 and is headquartered in Paris, France.